APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NK1/NK3 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026

Report ID 174017370423 December 2025208 pages

Choose your research edition.

Industry ResearchNK1/NK3 Receptor Antagonists Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NK1/NK3 Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NK1/NK3 Receptor Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NK1/NK3 Receptor Antagonists market include Chia Tai Tianqing Pharmaceutical, Yichang Humanwell Pharmaceutical, Qilu Pharmaceutical, Merck, Luoxin Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Helsinn Healthcare, Hansoh Pharma and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NK1/NK3 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NK1/NK3 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NK1/NK3 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NK1/NK3 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

NK1/NK3 Receptor Antagonists Segment by Company

Chia Tai Tianqing Pharmaceutical

Yichang Humanwell Pharmaceutical

Qilu Pharmaceutical

Merck

Luoxin Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Helsinn Healthcare

Hansoh Pharma

Fresenius Kabi

Beijing Sihuan Pharmaceutical

Bayer

Astellas

Torrent Pharmaceuticals

TerSera Therapeutics

Heron Therapeutics

Glenmark

NK1/NK3 Receptor Antagonists Segment by Type

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

NK1/NK3 Receptor Antagonists Segment by Application

Hospital

Specialty Clinic

NK1/NK3 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NK1/NK3 Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions NK1/NK3 Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NK1/NK3 Receptor Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze NK1/NK3 Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1/NK3 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1/NK3 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1/NK3 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NK1/NK3 Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK1/NK3 Receptor Antagonists industry.

Chapter 3: Detailed analysis of NK1/NK3 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of NK1/NK3 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of NK1/NK3 Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NK1/NK3 Receptor Antagonists Industry Trends Table 2. NK1/NK3 Receptor Antagonists Industry Drivers Table 3. NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges Table 4. NK1/NK3 Receptor Antagonists Industry Restraints Table 5. Global NK1/NK3 Receptor Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NK1/NK3 Receptor Antagonists Revenue Share by Company (2021-2026) Table 7. Global NK1/NK3 Receptor Antagonists Sales Volume by Company (k units) & (2021-2026) Table 8. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global NK1/NK3 Receptor Antagonists Average Price (USD/unit) of Company (2021-2026) Table 10. Global NK1/NK3 Receptor Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global NK1/NK3 Receptor Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global NK1/NK3 Receptor Antagonists Company, Product Type & Application Table 13. Global NK1/NK3 Receptor Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global NK1/NK3 Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of NK1 Receptor Antagonist Table 18. Significant Companies of NK3 Receptor Antagonist Table 19. Significant Companies of Dual Antagonist Table 20. Global NK1/NK3 Receptor Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global NK1/NK3 Receptor Antagonists Sales Volume by Type (2021-2026) & (k units) Table 22. Global NK1/NK3 Receptor Antagonists Sales Volume by Type (2027-2032) & (k units) Table 23. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Type (2021-2026) Table 24. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Type (2027-2032) Table 25. Global NK1/NK3 Receptor Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global NK1/NK3 Receptor Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global NK1/NK3 Receptor Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global NK1/NK3 Receptor Antagonists Sales Value Share by Type (2021-2026) Table 29. Global NK1/NK3 Receptor Antagonists Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Specialty Clinic Table 32. Global NK1/NK3 Receptor Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global NK1/NK3 Receptor Antagonists Sales Volume by Application (2021-2026) & (k units) Table 34. Global NK1/NK3 Receptor Antagonists Sales Volume by Application (2027-2032) & (k units) Table 35. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Application (2021-2026) Table 36. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Application (2027-2032) Table 37. Global NK1/NK3 Receptor Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global NK1/NK3 Receptor Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global NK1/NK3 Receptor Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global NK1/NK3 Receptor Antagonists Sales Value Share by Application (2021-2026) Table 41. Global NK1/NK3 Receptor Antagonists Sales Value Share by Application (2027-2032) Table 42. Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (k units) Table 44. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 45. Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032) & (k units) Table 46. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region (2027-2032) Table 47. Global NK1/NK3 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global NK1/NK3 Receptor Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global NK1/NK3 Receptor Antagonists Sales Value Share by Region (2021-2026) Table 50. Global NK1/NK3 Receptor Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global NK1/NK3 Receptor Antagonists Sales Value Share by Region (2027-2032) Table 52. Global NK1/NK3 Receptor Antagonists Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global NK1/NK3 Receptor Antagonists Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global NK1/NK3 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 57. Global NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 58. Global NK1/NK3 Receptor Antagonists Sales by Country (2027-2032) & (k units) Table 59. Global NK1/NK3 Receptor Antagonists Sales Market Share by Country (2027-2032) Table 60. Global NK1/NK3 Receptor Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global NK1/NK3 Receptor Antagonists Sales Value Market Share by Country (2021-2026) Table 62. Global NK1/NK3 Receptor Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global NK1/NK3 Receptor Antagonists Sales Value Market Share by Country (2027-2032) Table 64. Chia Tai Tianqing Pharmaceutical Company Information Table 65. Chia Tai Tianqing Pharmaceutical Business Overview Table 66. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 68. Chia Tai Tianqing Pharmaceutical Recent Development Table 69. Yichang Humanwell Pharmaceutical Company Information Table 70. Yichang Humanwell Pharmaceutical Business Overview Table 71. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 73. Yichang Humanwell Pharmaceutical Recent Development Table 74. Qilu Pharmaceutical Company Information Table 75. Qilu Pharmaceutical Business Overview Table 76. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 78. Qilu Pharmaceutical Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 82. Merck NK1/NK3 Receptor Antagonists Product Portfolio Table 83. Merck Recent Development Table 84. Luoxin Pharmaceutical Company Information Table 85. Luoxin Pharmaceutical Business Overview Table 86. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 88. Luoxin Pharmaceutical Recent Development Table 89. Jiangsu Hengrui Pharmaceuticals Company Information Table 90. Jiangsu Hengrui Pharmaceuticals Business Overview Table 91. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 93. Jiangsu Hengrui Pharmaceuticals Recent Development Table 94. Helsinn Healthcare Company Information Table 95. Helsinn Healthcare Business Overview Table 96. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio Table 98. Helsinn Healthcare Recent Development Table 99. Hansoh Pharma Company Information Table 100. Hansoh Pharma Business Overview Table 101. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio Table 103. Hansoh Pharma Recent Development Table 104. Fresenius Kabi Company Information Table 105. Fresenius Kabi Business Overview Table 106. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio Table 108. Fresenius Kabi Recent Development Table 109. Beijing Sihuan Pharmaceutical Company Information Table 110. Beijing Sihuan Pharmaceutical Business Overview Table 111. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 113. Beijing Sihuan Pharmaceutical Recent Development Table 114. Bayer Company Information Table 115. Bayer Business Overview Table 116. Bayer NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Bayer NK1/NK3 Receptor Antagonists Product Portfolio Table 118. Bayer Recent Development Table 119. Astellas Company Information Table 120. Astellas Business Overview Table 121. Astellas NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Astellas NK1/NK3 Receptor Antagonists Product Portfolio Table 123. Astellas Recent Development Table 124. Torrent Pharmaceuticals Company Information Table 125. Torrent Pharmaceuticals Business Overview Table 126. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 128. Torrent Pharmaceuticals Recent Development Table 129. TerSera Therapeutics Company Information Table 130. TerSera Therapeutics Business Overview Table 131. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 133. TerSera Therapeutics Recent Development Table 134. Heron Therapeutics Company Information Table 135. Heron Therapeutics Business Overview Table 136. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 138. Heron Therapeutics Recent Development Table 139. Glenmark Company Information Table 140. Glenmark Business Overview Table 141. Glenmark NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Glenmark NK1/NK3 Receptor Antagonists Product Portfolio Table 143. Glenmark Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. NK1/NK3 Receptor Antagonists Distributors List Table 147. NK1/NK3 Receptor Antagonists Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. NK1/NK3 Receptor Antagonists Product Image Figure 2. Global NK1/NK3 Receptor Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global NK1/NK3 Receptor Antagonists Sales (2021-2032) & (k units) Figure 5. Global NK1/NK3 Receptor Antagonists Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global NK1/NK3 Receptor Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. NK1 Receptor Antagonist Image Figure 10. NK3 Receptor Antagonist Image Figure 11. Dual Antagonist Image Figure 12. Global NK1/NK3 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global NK1/NK3 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Type (2021-2032) Figure 15. Global NK1/NK3 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global NK1/NK3 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global NK1/NK3 Receptor Antagonists Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Specialty Clinic Image Figure 20. Global NK1/NK3 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global NK1/NK3 Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global NK1/NK3 Receptor Antagonists Sales Volume Share by Application (2021-2032) Figure 23. Global NK1/NK3 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global NK1/NK3 Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global NK1/NK3 Receptor Antagonists Sales Value Share by Application (2021-2032) Figure 26. Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global NK1/NK3 Receptor Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global NK1/NK3 Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global NK1/NK3 Receptor Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 31. North America NK1/NK3 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 33. Europe NK1/NK3 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. South America NK1/NK3 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa NK1/NK3 Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. NK1/NK3 Receptor Antagonists Value Chain Figure 125. Manufacturing Cost Structure Figure 126. NK1/NK3 Receptor Antagonists Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • NK1 Receptor Antagonist
  • NK3 Receptor Antagonist
  • Dual Antagonist
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Luoxin Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Helsinn Healthcare
  • Hansoh Pharma
  • Fresenius Kabi
  • Beijing Sihuan Pharmaceutical
  • Bayer
  • Astellas
  • Torrent Pharmaceuticals
  • TerSera Therapeutics
  • Heron Therapeutics
  • Glenmark

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global NK1/NK3 Receptor Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global NK1/NK3 Receptor Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 NK1/NK3 Receptor Antagonists Market Dynamics
  1. 2.1 NK1/NK3 Receptor Antagonists Industry Trends
  2. 2.2 NK1/NK3 Receptor Antagonists Industry Drivers
  3. 2.3 NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK1/NK3 Receptor Antagonists Industry Restraints
3 NK1/NK3 Receptor Antagonists Market by Company
  1. 3.1 Global NK1/NK3 Receptor Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global NK1/NK3 Receptor Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global NK1/NK3 Receptor Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global NK1/NK3 Receptor Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global NK1/NK3 Receptor Antagonists Company Ranking (2024-2026)
  6. 3.6 Global NK1/NK3 Receptor Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global NK1/NK3 Receptor Antagonists Company Product Type and Application
  8. 3.8 Global NK1/NK3 Receptor Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global NK1/NK3 Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 NK1/NK3 Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 NK1/NK3 Receptor Antagonists Market by Type
  1. 4.1 NK1/NK3 Receptor Antagonists Type Introduction
  2. 4.1.1 NK1 Receptor Antagonist
  3. 4.1.2 NK3 Receptor Antagonist
  4. 4.1.3 Dual Antagonist
  5. 4.2 Global NK1/NK3 Receptor Antagonists Sales Volume by Type
  6. 4.2.1 Global NK1/NK3 Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global NK1/NK3 Receptor Antagonists Sales Volume by Type (2021-2032)
  8. 4.2.3 Global NK1/NK3 Receptor Antagonists Sales Volume Share by Type (2021-2032)
  9. 4.3 Global NK1/NK3 Receptor Antagonists Sales Value by Type
  10. 4.3.1 Global NK1/NK3 Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global NK1/NK3 Receptor Antagonists Sales Value by Type (2021-2032)
  12. 4.3.3 Global NK1/NK3 Receptor Antagonists Sales Value Share by Type (2021-2032)
5 NK1/NK3 Receptor Antagonists Market by Application
  1. 5.1 NK1/NK3 Receptor Antagonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Specialty Clinic
  4. 5.2 Global NK1/NK3 Receptor Antagonists Sales Volume by Application
  5. 5.2.1 Global NK1/NK3 Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NK1/NK3 Receptor Antagonists Sales Volume by Application (2021-2032)
  7. 5.2.3 Global NK1/NK3 Receptor Antagonists Sales Volume Share by Application (2021-2032)
  8. 5.3 Global NK1/NK3 Receptor Antagonists Sales Value by Application
  9. 5.3.1 Global NK1/NK3 Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global NK1/NK3 Receptor Antagonists Sales Value by Application (2021-2032)
  11. 5.3.3 Global NK1/NK3 Receptor Antagonists Sales Value Share by Application (2021-2032)
6 NK1/NK3 Receptor Antagonists Regional Sales and Value Analysis
  1. 6.1 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global NK1/NK3 Receptor Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032)
  5. 6.3 Global NK1/NK3 Receptor Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global NK1/NK3 Receptor Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global NK1/NK3 Receptor Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global NK1/NK3 Receptor Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global NK1/NK3 Receptor Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America NK1/NK3 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe NK1/NK3 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America NK1/NK3 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa NK1/NK3 Receptor Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa NK1/NK3 Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
7 NK1/NK3 Receptor Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NK1/NK3 Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global NK1/NK3 Receptor Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global NK1/NK3 Receptor Antagonists Sales by Country (2027-2032)
  6. 7.4 Global NK1/NK3 Receptor Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global NK1/NK3 Receptor Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global NK1/NK3 Receptor Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt NK1/NK3 Receptor Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt NK1/NK3 Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt NK1/NK3 Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Yichang Humanwell Pharmaceutical
  8. 8.2.1 Yichang Humanwell Pharmaceutical Company Information
  9. 8.2.2 Yichang Humanwell Pharmaceutical Business Overview
  10. 8.2.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  12. 8.2.5 Yichang Humanwell Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck NK1/NK3 Receptor Antagonists Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Luoxin Pharmaceutical
  26. 8.5.1 Luoxin Pharmaceutical Company Information
  27. 8.5.2 Luoxin Pharmaceutical Business Overview
  28. 8.5.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  30. 8.5.5 Luoxin Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Hengrui Pharmaceuticals
  32. 8.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 8.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 8.6.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 8.7 Helsinn Healthcare
  38. 8.7.1 Helsinn Healthcare Company Information
  39. 8.7.2 Helsinn Healthcare Business Overview
  40. 8.7.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio
  42. 8.7.5 Helsinn Healthcare Recent Developments
  43. 8.8 Hansoh Pharma
  44. 8.8.1 Hansoh Pharma Company Information
  45. 8.8.2 Hansoh Pharma Business Overview
  46. 8.8.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio
  48. 8.8.5 Hansoh Pharma Recent Developments
  49. 8.9 Fresenius Kabi
  50. 8.9.1 Fresenius Kabi Company Information
  51. 8.9.2 Fresenius Kabi Business Overview
  52. 8.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio
  54. 8.9.5 Fresenius Kabi Recent Developments
  55. 8.10 Beijing Sihuan Pharmaceutical
  56. 8.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 8.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 8.10.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  60. 8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bayer NK1/NK3 Receptor Antagonists Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Astellas
  68. 8.12.1 Astellas Company Information
  69. 8.12.2 Astellas Business Overview
  70. 8.12.3 Astellas NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Astellas NK1/NK3 Receptor Antagonists Product Portfolio
  72. 8.12.5 Astellas Recent Developments
  73. 8.13 Torrent Pharmaceuticals
  74. 8.13.1 Torrent Pharmaceuticals Company Information
  75. 8.13.2 Torrent Pharmaceuticals Business Overview
  76. 8.13.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  78. 8.13.5 Torrent Pharmaceuticals Recent Developments
  79. 8.14 TerSera Therapeutics
  80. 8.14.1 TerSera Therapeutics Company Information
  81. 8.14.2 TerSera Therapeutics Business Overview
  82. 8.14.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  84. 8.14.5 TerSera Therapeutics Recent Developments
  85. 8.15 Heron Therapeutics
  86. 8.15.1 Heron Therapeutics Company Information
  87. 8.15.2 Heron Therapeutics Business Overview
  88. 8.15.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  90. 8.15.5 Heron Therapeutics Recent Developments
  91. 8.16 Glenmark
  92. 8.16.1 Glenmark Company Information
  93. 8.16.2 Glenmark Business Overview
  94. 8.16.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Glenmark NK1/NK3 Receptor Antagonists Product Portfolio
  96. 8.16.5 Glenmark Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NK1/NK3 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 NK1/NK3 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NK1/NK3 Receptor Antagonists Sales Mode & Process
  6. 9.2 NK1/NK3 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NK1/NK3 Receptor Antagonists Distributors
  9. 9.2.3 NK1/NK3 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst